Neuroblastoma (NB) is a tumor usually arising in children and young adults showing different degrees of malignancy. Recently, the presence of N-myc amplification in neuroblasts has been associated with a poor outcome in the late stages of disease (Evans's Stage IV). Until now no amplification of N-myc gene has been observed in Stage IV-S, usually considered to have a favorable prognosis. In this paper we report a case of a child affected by NB Stage IV-S showing mild N-myc gene amplification. The finding of N-myc amplification in our patient shows that such alteration of the N-myc oncogene is not necessarily correlated with a poor prognosis; in this light the role of N-myc amplification in the neoplastic process should be reconsidered.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/00043426-198721000-00002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Multicellular model of neuroblastoma proposes unconventional therapy based on multiple roles of p53.
PLoS Comput Biol
December 2024
Insigneo Institute for in Silico Medicine, University of Sheffield, Sheffield, United Kingdom.
Neuroblastoma is the most common extra-cranial solid tumour in children. Over half of all high-risk cases are expected to succumb to the disease even after chemotherapy, surgery, and immunotherapy. Although the importance of MYCN amplification in this disease is indisputable, the mechanistic details remain enigmatic.
View Article and Find Full Text PDFSimultaneous single-nucleus RNA sequencing and single-nucleus ATAC sequencing of neuroblastoma cell lines.
Sci Data
November 2024
Department of Pediatric Surgery, Massachusetts General Hospital, Boston, MA, USA.
Neuroblastoma is the most common extracranial solid tumor in children, and a leading cause of childhood cancer deaths. All neuroblastomas arise from neural crest-derived sympathetic neuronal progenitors, but numerous mutations, the most common of which is MYCN amplification, give rise to these lesions. Epigenetic aberrations also play a role in oncogenesis and tumor progression.
View Article and Find Full Text PDFDifferentiating MYCN-amplified RB1 wild-type retinoblastoma from biallelic RB1 mutant retinoblastoma using MR-based radiomics: a retrospective multicenter case-control study.
Sci Rep
October 2024
European Retinoblastoma Imaging Collaboration (ERIC), Amsterdam, The Netherlands.
MYCN-amplified RB1 wild-type (MYCNRB1) retinoblastoma is a rare and aggressive subtype, often resistant to standard therapies. Identifying unique MRI features is crucial for diagnosing this subtype, as biopsy is not recommended. This study aimed to differentiate MYCNRB1 from the most prevalent RB1 retinoblastoma using pretreatment MRI and radiomics.
View Article and Find Full Text PDFEvent-free survival in neuroblastoma with MYCN amplification and deletion of 1p or 11q may be associated with altered immune status.
BMC Cancer
October 2024
Department of Pediatric Oncology, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, West Huan-Hu Rd, Ti Yuan Bei, Hexi District, 300060, Tianjin, Tianjin, China.
Article Synopsis
- Neuroblastoma shows significant genetic diversity, impacting patient immune status and prognosis, prompting a study of 31 patients with varying genetic traits.
- Testing revealed that 22 patients had genetic alterations, particularly MYCN amplification and chromosome deletions, which correlated with worse event-free survival (EFS) rates.
- An increase in regulatory T cells and cytokines like interleukin-10 (IL-10) was observed, indicating an immunosuppressive environment that further worsens EFS, especially among patients with high IL-10 levels.
Golgi-localized Ring Finger Protein 121 is necessary for MYCN-driven neuroblastoma tumorigenesis.
Commun Biol
October 2024
Children's Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, UNSW Sydney, Sydney, Australia.
Article Synopsis
- - MYCN amplification is linked to poor outcomes in childhood neuroblastoma and the study investigates the signaling dependencies associated with it through genetic manipulation in mice.
- - A mutation in the RNF121 gene was found to result in decreased tumor formation, with RNF121 playing a crucial role in enhancing MYCN protein stability and contributing to tumor growth.
- - Elevated RNF121 levels correlate with poor prognosis in neuroblastoma and laryngeal cancer, suggesting it as a potential target for new cancer therapies.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!